Mostrar el registro sencillo del documento

dc.creatorZhang, Rui
dc.creatorWang, Xuebin
dc.creatorNi, Leng
dc.creatorDi, Xiao
dc.creatorMa, Baitao
dc.creatorNiu, Shuai
dc.creatorLiu, Changwei
dc.creatorReiter, Russel J.
dc.date.accessioned2020-09-07T17:12:02Z
dc.date.available2020-09-07T17:12:02Z
dc.date.created2020-06-01
dc.identifier.issn0024-3205spa
dc.identifier.otherhttps://www.sciencedirect.com/science/article/pii/S0024320520303313?via%3Dihubspa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/12845
dc.format.extent6 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherLife Sciencesspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.titleCOVID-19: Melatonin as a potential adjuvant treatmentspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAcceso restringidospa
dc.subject.keywordMelatoninspa
dc.subject.keywordOxidationspa
dc.subject.keywordCytokinesspa
dc.subject.keywordImmunomodulationspa
dc.subject.keywordOxidation-reductionspa
dc.identifier.doihttps://doi.org/10.1016/j.lfs.2020.117583spa
dc.description.abstractenglishThis article summarizes the likely benefits of melatonin in the attenuation of COVID-19 based on its putative pathogenesis. The recent outbreak of COVID-19 has become a pandemic with tens of thousands of infected patients. Based on clinical features, pathology, the pathogenesis of acute respiratory disorder induced by either highly homogenous coronaviruses or other pathogens, the evidence suggests that excessive inflammation, oxidation, and an exaggerated immune response very likely contribute to COVID-19 pathology. This leads to a cytokine storm and subsequent progression to acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and often death. Melatonin, a well-known anti-inflammatory and anti-oxidative molecule, is protective against ALI/ARDS caused by viral and other pathogens. Melatonin is effective in critical care patients by reducing vessel permeability, anxiety, sedation use, and improving sleeping quality, which might also be beneficial for better clinical outcomes for COVID-19 patients. Notably, melatonin has a high safety profile. There is significant data showing that melatonin limits virus-related diseases and would also likely be beneficial in COVID-19 patients. Additional experiments and clinical studies are required to confirm this speculation.spa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa


Archivos en el documento

ArchivosTamañoFormatoVer

No hay archivos asociados a este documento.

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento